Mylan Inc. said Monday it is now selling a generic version of Xibrom eye drops, which were discontinued in February by their original maker, ISTA Pharmaceuticals Inc.
Xibrom is a twice-per-day eye drop designed to treat eye inflammation in patients recovering from cataract surgery. ISTA discontinued Xibrom after a once-per-day version of the same drug, Bromday, was approved by the Food and Drug Administration.
The active ingredient in Bromday and Xibrom is bromfenac. Mylan said U.S. sales of bromfenac solutions totaled $116 million over the 12 months ended March 31.
ISTA, which is based in Irvine, Calif., received FDA approval for Bromday in November. It discontinued sales of Xibrom in February.
Shares of Mylan fell 17 cents to $23.92 in morning trading.